October 9, 2015
Long-term treatment of patients with juvenile idiopathic arthritis with Orencia for up to 7 years may be beneficial, according to recently published research.
Researchers studied 190 patients with juvenile idiopathic arthritis (JIA) aged 6 to 17 years in Europe, Latin America and the U.S. enrolled in either the Pediatric Rheumatology Collaborative Study Group or the Paediatric Rheumatology International Trials Organisation phase 3 trial. The study design had a 4-month open-label lead-in phase in which all participants received IV Orencia (abatacept, Bristol-Meyers Squibb) at 10 mg/kg followed by a 6-month, double-blind withdrawal phase. Upon enrollment, included patients had active disease in at least two joints with a history of involvement in at least five joints, while the average number of active joints in patients was 16.